66564-14-5

66564-14-5 structure

Name: Cinitapride
Chemical Name: 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
CAS Number: 66564-14-5
Molecular Formula: C₂₁H₃₀N₄O₄
Molecular Weight: 402.487
Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
Create Date: 2018-04-02 08:00:00
Modify Date: 2025-08-21 19:15:50
Cinitapride is an orally active 5-HT4 agonist and D2 antagonist. Cinitapride shows gastroprotective properties on mucosal injury. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research[1][2][3].

Name	4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
Synonyms	Cinitaprida 4-Amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide cidine Cinitapridum Blaston cinitapride Cinmove Paxapride 4-Amino-N-[1-(3-cyclohexen-1-ylmethyl)-4-piperidinyl]-2-ethoxy-5-nitrobenzamide Cintapro Benzamide, 4-amino-N-[1-(3-cyclohexen-1-ylmethyl)-4-piperidinyl]-2-ethoxy-5-nitro-

Description	Cinitapride is an orally active 5-HT4 agonist and D2 antagonist. Cinitapride shows gastroprotective properties on mucosal injury. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research[1][2][3].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
In Vivo	Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model[2]. Animal Model: Male Wistar rats with gastric ulceration[2] Dosage: 0.25-1 mg/kg Administration: Intraperitoneal injection; 0.25-1 mg/kg; once Result: Reduced haemorrhagic lesions compared with the ulcerated control group. Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg). Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01). Increased GSH-px activity in the gastric mucosa.